1. Israel Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
NEXTAGE Therapeutics Ltd.

NEXTAGE Therapeutics Ltd.

TTASE:NXTG
37.40
ILA
+0.60
(+1.63%)
6.31BMarket Cap
NEXTAGE Therapeutics Ltd.
TASE:NXTG
(Tel Aviv Stock Exchange)

Recent

price

37.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
ILS
0.06
0.49
- -
0.38
0.02
- -
- -
0.25
0.1
0.09
- -
Revenue per Share
-18.28
-6.98
-1.21
-2.51
-1.4
-0.3
-0.2
0.06
-0.26
-0.15
- -
Basic EPS, GAAP
-14.68
-6.92
-3.43
-2.61
-0.55
-0.15
-0.22
-0.11
0.02
-0.16
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
3.93
-1.43
-2.46
0.06
-0.01
-0.03
-0.1
-0.6
0.18
0.18
Book Value per Share
- -
-4.02
-5.49
-2.46
0.01
-0.01
-0.03
-0.1
-0.6
-0.36
-0.36
Tangible Book Value per Share
- -
1
1
2
11
26
28
30
34
42
81
Basic Weighted Avg Shares
- -
- -
- -
1
- -
- -
- -
8
3
4
- -
Sales/Revenue/Turnover
-25,539.29
-1,462.96
- -
-634.81
-3,348.69
-7,825.27
- -
-69.76
-169.67
-226.46
- -
Operating Margin (%)
1
1
- -
- -
- -
- -
- -
2
1
2
- -
Depreciation Expense
-9
-6
-2
-5
-16
-8
-6
2
-9
-6
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-31,235.71
-1,415.31
- -
-653.3
-8,359.16
-8,492.31
- -
24.84
-273.49
-168.48
- -
Profit Margin (%)
- -
2
-1
-5
1
2
- -
-3
-20
-27
-27
Working Capital
- -
2
1
1
1
1
- -
- -
3
3
3
LT Debt
- -
4
-2
-6
1
1
- -
-3
-20
14
14
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
9
9
14
LT Borrowings
2
3
3
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
34
81
Market Capitalization
26
36
63

Working Capital

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1
1
2
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
1
1
Inventories
- -
- -
- -
Total Current Liabilities
21
23
29
Payables & Accruals
- -
- -
- -
ST Debt
9
9
14
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
152.22%
-169.13%
Free Cash Flow
- -
-250.15%
-1,102.93%
Net Income, GAAP
- -
-162.02%
-31.27%
Sales/Revenue/Turnover
- -
- -
11.57%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
8
2024
- -
- -
3
2025
- -
- -
4

Semi-annual Earnings Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.06
2024
- -
- -
-0.26
2025
- -
- -
-0.15

Semi-annual Dividends Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Nextage Therapeutics Ltd is an Israeli biotechnology firm concentrating on advanced drug delivery systems for the central nervous system. The company specializes in innovative technologies designed to transport medications effectively across the blood-brain barrier, aiming to address conditions such as Alzheimer's, Parkinson's, and certain cancers. While previously involved in cannabinoid-based and psychedelic product development through a merged subsidiary, its primary emphasis now centers on its Brain Targeting Liposome System (BTLS) platform. The company is based in Ness Ziona.